Introduction
Healthcare antitrust is more nuanced than the simple narrative of "new administration, less enforcement" suggests. The current FTC is generally more permissive toward large-scale M&A and clearly willing to settle for divestitures rather than litigate, yet healthcare has produced both its highest-profile courtroom win and its heaviest remedy packages. For bankers, the enforcement landscape drives timeline planning, structure, and deal certainty.
Current Enforcement Posture
Three areas absorb most of the FTC's healthcare attention.
Device pipelines, not just device markets. The agency's most important healthcare win came in a market with no approved product. In August 2025 the FTC challenged Edwards Lifesciences' $945 million acquisition of JenaValve Technology, alleging the two were the only companies running US clinical trials for transcatheter aortic valve replacement devices treating aortic regurgitation (TAVR-AR devices), a field Edwards had already consolidated by acquiring JC Medical in 2024. After a six-day trial, the District Court for the District of Columbia granted a preliminary injunction on January 9, 2026, and Edwards abandoned the deal. The FTC characterised the ruling as a victory halting an anticompetitive medical device deal. This was a two-to-one case about clinical pipelines, not a share-of-market challenge in commercial TAVR, which is why it matters well beyond cardiology.
- Innovation Market Theory
An antitrust theory under which the FTC challenges an acquisition not because it reduces competition in an existing product market but because it eliminates a future competitive threat. In healthcare the agency applies it where an acquirer buys a clinical-stage rival whose pipeline would eventually compete with its own, or, as in Edwards/JenaValve, where both products are pre-approval and the deal would leave one developer where there were two. A target with no revenue and no approved product can still trigger a challenge.
Private equity roll-ups, reframed. The FTC has not filed a new serial-acquisition complaint since its 2023 case against U.S. Anesthesia Partners and Welsh Carson, resolved by a consent order with the sponsor and a settlement with the platform, and current leadership has signalled that private equity ownership is not by itself a theory of harm. Sponsor-backed platforms still face structural remedies, though. Centerbridge-owned Sevita cleared its $835 million purchase of BrightSpring's community living business only by divesting 128 intermediate care facilities across Indiana, Louisiana, and Texas. Anyone modelling how sponsors build and exit healthcare platforms should treat divestiture risk, not challenge risk, as the base case.
Healthcare labor and staffing infrastructure. Aya Healthcare agreed in December 2024 to acquire Cross Country Healthcare for roughly $615 million, then let the merger agreement lapse in December 2025 rather than extend a review already a year old. The FTC never sued. Its Bureau of Competition said the deal would have eliminated head-to-head competition between two of the largest suppliers of the software and services hospitals use to find, hire, and manage travel nurses. The theory ran through hospital costs and worker options rather than classic localized wage suppression, but the lesson holds: deals touching healthcare labor supply chains draw long reviews, and review length alone can kill a transaction.
Remedies, Not Blocks, Define Most Outcomes
The 2026 pattern is settlement with structure attached. Ascension Health's $3.9 billion acquisition of AmSurg cleared in June 2026 after Ascension agreed to divest seven ambulatory surgery centers in five metro areas where the FTC alleged reduced competition for outpatient gastroenterology, ophthalmology, and orthopedic procedures.
Both that order and the Sevita order carry ten-year advance-notice obligations on future acquisitions in the affected geographies. That is the underappreciated cost: a buyer accepting a remedy is not simply selling assets, it is running its tuck-in strategy under supervision for a decade, which affects the platform's growth story and its exit multiple.
State-Level Enforcement Expansion
The more structural change is state review authority. Roughly a dozen states now operate healthcare-specific transaction notice or approval regimes, including California, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, Nevada, New York, Oregon, Vermont, and Washington. Further bills appear every session.
The requirements vary widely. Some reach only hospital mergers, others cover physician practice acquisitions, and several are written to capture private equity, management services organizations, and real estate structures. Advance notice periods alone run from 60 days in Massachusetts, Rhode Island, and Washington, to 90 days under California's Office of Health Care Affordability regime, to 180 days under the Maine law effective January 2027. The result is a patchwork that adds timeline and cost, especially for multi-state roll-ups where one add-on can trigger notices in several states at once.
Antitrust analysis belongs at the front of a transaction, not the end. Federal pipeline theories, remedy-heavy settlements, and expanding state review affect deal certainty, timeline, and the value a buyer retains after closing.
The next article examines healthcare capital markets in 2026 and the state of the biotech IPO market.
